Additionally, resveratrol reduces lipoprotein(a) [Lp(a)] levels, hepatic 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity, and cholesterol ester transport protein concentrations while increasing apolipoprotein A1 (ApoA1), effectively ameliorating dyslipidemia (66). Here, APOA1 is linked to metabolic syndrome.